文献速递胸部肿瘤

早期非鳞状非小细胞肺癌个体化免疫预后标签的建立与验证

Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
PubMed 文献 · JAMA Oncol · 2017-01-01

这项回顾性研究分析19个公开非小细胞肺癌队列的2414例非鳞状非小细胞肺癌患者基因表达数据,构建由25个基因对(40个独特基因)组成的免疫预后标签。该标签在验证队列中可显著区分高低风险组的总生存,并作为独立预后因素(风险比范围1.72至2.36),与临床特征整合后预后准确性提高。作者认为该标签是有前景的生物标志物,需前瞻性研究验证其临床效用。

要点

  • 基于19个公开队列2414例非鳞状非小细胞肺癌患者构建25个基因对的免疫预后标签。
  • 免疫标签在验证队列中显著区分高低风险组总生存,多因素分析风险比范围1.72至2.36。
  • 免疫标签联合年龄和分期等临床特征后预后准确性提高(平均C指数0.70对0.63)。

核心结论

  • 提出的临床-免疫标签是估计非鳞状非小细胞肺癌(包括早期疾病)总生存的有前景的生物标志物。
  • 需要前瞻性研究来检验该生物标志物在非鳞状非小细胞肺癌个体化管理中的临床效用。

研究设计与样本

  • 这项回顾性研究分析19个公开非小细胞肺癌队列的冷冻肿瘤组织样本基因表达谱,包括18个微阵列数据集和1个癌症基因组图谱(TCGA)肺腺癌队列的RNA-Seq数据集。
  • 仅纳入具有临床注释的非鳞状非小细胞肺癌患者,样本来自2414例患者,分为元训练队列(729例)、元测试队列(716例)和3个独立验证队列(439例、323例和207例)。
  • 所有患者接受手术且手术切缘阴性,未接受辅助或新辅助治疗,并具有公开可用的基因表达数据和生存信息。
  • 数据收集时间为2016年7月22日至2016年9月8日。

主要发现

  • 2414例患者中(1205例男性[50%]、1111例女性[46%]、98例性别未知[4%];中位年龄[范围]64[15-90]岁),利用元训练数据集构建了由25个基因对(包含40个独特基因)组成的预后免疫标签。
  • 在元测试和验证队列中,免疫标签在I期、IA期、IB期或II期疾病的亚组间和亚组内均能显著将患者按总生存分为高风险组与低风险组,并在调整临床和病理因素后的多因素分析中保持为独立预后因素(风险比范围1.72[95%CI,1.26-2.33;P<.001]至2.36[95%CI,1.47-3.79;P<.001])。
  • 免疫标签中的基因富集于包括趋化性在内的若干生物学过程。
  • 在TCGA数据集中,高风险免疫组的中性粒细胞浸润百分比(5.6%对1.8%)和坏死百分比(4.6%对1.5%)显著高于低风险组(P<.003)。
  • 在可比较的验证队列中,免疫标签估计生存的准确性(平均一致性指数[C指数]0.64)高于2个商业化多基因标签(平均C指数分别为0.53和0.61)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The prevalence of early-stage non-small cell lung cancer (NSCLC) is expected to increase with recent implementation of annual screening programs. Reliable prognostic biomarkers are needed to identify patients at a high risk for recurrence to guide adjuvant therapy. OBJECTIVE: To develop a robust, individualized immune signature that can estimate prognosis in patients with early-stage nonsquamous NSCLC. DESIGN, SETTING, AND PARTICIPANTS: This retrospective study analyzed the gene expression profiles of frozen tumor tissue samples from 19 public NSCLC cohorts, including 18 microarray data sets and 1 RNA-Seq data set for The Cancer Genome Atlas (TCGA) lung adenocarcinoma cohort. Only patients with nonsquamous NSCLC with clinical annotation were included. Samples were from 2414 patients with nonsquamous NSCLC, divided into a meta-training cohort (729 patients), meta-testing cohort (716 patients), and 3 independent validation cohorts (439, 323, and 207 patients). All patients underwent surgery with a negative surgical margin, received no adjuvant or neoadjuvant therapy, and had publicly available gene expression data and survival information. Data were collected from July 22 through September 8, 2016. MAIN OUTCOMES AND MEASURES: Overall survival. RESULTS: Of 2414 patients (1205 men [50%], 1111 women [46%], and 98 of unknown sex [4%]; median age [range], 64 [15-90] years), a prognostic immune signature of 25 gene pairs consisting of 40 unique genes was constructed using the meta-training data set. In the meta-testing and validation cohorts, the immune signature significantly stratified patients into high- vs low-risk groups in terms of overall survival across and within subpopulations with stage I, IA, IB, or II disease and remained as an independent prognostic factor in multivariate analyses (hazard ratio range, 1.72 [95% CI, 1.26-2.33; P < .001] to 2.36 [95% CI, 1.47-3.79; P < .001]) after adjusting for clinical and pathologic factors. Several biological processes, including chemotaxis, were enriched among genes in the immune signature. The percentage of neutrophil infiltration (5.6% vs 1.8%) and necrosis (4.6% vs 1.5%) was significantly higher in the high-risk immune group compared with the low-risk groups in TCGA data set (P < .003). The immune signature achieved a higher accuracy (mean concordance index [C-index], 0.64) than 2 commercialized multigene signatures (mean C-index, 0.53 and 0.61) for estimation of survival in comparable validation cohorts. When integrated with clinical characteristics such as age and stage, the composite clinical and immune signature showed improved prognostic accuracy in all validation data sets relative to molecular signatures alone (mean C-index, 0.70 vs 0.63) and another commercialized clinical-molecular signature (mean C-index, 0.68 vs 0.65). CONCLUSIONS AND RELEVANCE: The proposed clinical-immune signature is a promising biomarker for estimating overall survival in nonsquamous NSCLC, including early-stage disease. Prospective studies are needed to test the clinical utility of the biomarker in individualized management of nonsquamous NSCLC.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Li B, Cui Y, Diehn M, et al. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer. JAMA Oncol. 2017. PMID: 28687838. doi:10.1001/jamaoncol.2017.1609

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。